EMERGING MOLECULAR MECHANISM AS THERAPEUTICS FOR ALZHEIMER’S

Abstract

Worldwide, there are more than 20 million people who have Alzheimer's disease (AD), a common neurological condition. Dysregulation of neuronal autophagy, a crucial cellular process responsible for protein degradation, has been determined to be a significant criterion in the emergence of AD and other neurodegenerative illnesses. Understanding the interplay between various elements of autophagy, such as Aβ and tau protein metabolism, the mTOR pathway, neuroinflammation, and the endocannabinoid system, holds promise for the creation of fresh treatment methods for AD. This research has the analysis of protein-protein interactions (PPI) and functional enrichment were both used for utilizing clinical data from the GDC data portal to identify key genes associated with AD. Differential expression analysis allowed us to distinguish genes with altered expression levels between mutant and normal groups. Among the genes identified, we focused on the small protein binding to GTP, RAB3B, a RAB family member implicated in cell autophagy. Disruptions in the RAB3B protein interactome have the potential to impair autophagy and exacerbate AD pathogenesis. To explore potential treatment options, we investigated stilbostemin C, a natural compound with therapeutic potential. In order to clarify the interactions between stilbostemin C and the RAB3B protein, molecular docking studies were carried out. The findings demonstrated stilbostemin C's strong affinity for RAB3B, pointing to its potential as a therapy candidate. vii The positive pharmacokinetic profile of stilbostemin C was also revealed by an ADMET study, confirming its potential for further research. In conclusion, this study clarifies the significance of autophagy. dysfunction in AD and highlights RAB3B as a potential target for therapeutic interventions. Moreover, stilbostemin C demonstrates promising interactions with RAB3B, suggesting its potential as a treatment option for AD. The therapeutic effectiveness of stilbostemin C and its suitability for upcoming investigations in the setting of AD both call for more investigation.